Key facts
- It has raised $500K; the latest was Early Stage VC ($400K) in Mar 2026.
- Notable investors include Lauder Partners, APEX Ventures, Airstream Venture Partners, Diana (England), R42 Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Swaza
- ·The full record, as it builds
Funding rounds
No funding rounds for Swaza are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Swaza
Developer of a nanofluid formulation intended to deliver oxygen to patients suffering from oxygen loss. The company's formulation can be used for the treatment of acute respiratory distress syndrome delivers oxygen directly to lung alveoli and removes carbon dioxide via over-the-counter nebulizers, enabling doctors to aid gas exchange in patients.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2022
- Employees
- 8
- Website
- swaza.life/
- Ownership
- Privately Held (backing)
Swaza doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Swaza shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Swaza in its N-PORT filings yet. We sweep new filings monthly.